Novartis India Reports Strong Q3 FY24-25 Results, Highlighting Operational Efficiency and Liquidity Improvement

Novartis India has recently reported its financial results for the third quarter of FY24-25, showcasing a notable performance within the pharmaceuticals and drugs sector. The company has experienced a positive shift in its evaluation, with its score reflecting a significant adjustment over the past three months. The financial data reveals that Novartis India achieved its highest quarterly net sales in the last five quarters, reaching Rs 93.00 crore. This upward trend in sales is complemented by an operating profit of Rs 25.58 crore, also the highest in the same timeframe, indicating enhanced operational efficiency. The operating profit margin has improved to 27.51%, further underscoring the company's effective management of resources. Additionally, the profit before tax, less other income, stands at Rs 24.69 crore, marking a year-on-year growth of 27.60%. This consistent performance is reflected in the company's cash and cash equivalents, which have reached Rs 597.24 crore, the highest in the last six half-yearly periods, suggesting an improvement in short-term liquidity. Overall, Novartis India’s recent financial results indicate a robust performance, leading to a revision in its score. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.